Tetragenetics

About:

Tetragenetics helps people seeking a cost-effective alternative platform technology for the production of genetically engineered proteins.

Website: http://www.tetragenetics.com

Twitter/X: Tetragenetics

Top Investors: National Institutes of Health, Bill & Melinda Gates Foundation, LaunchPad Venture, JDRF T1D Fund, NXT Ventures

Description:

Tetragenetics is an early-stage biotechnology company meeting the needs of customers who seek a cost-effective alternative platform technology for the production of genetically engineered proteins. Their technology is particularly well suited to the production of eucaryotic membrane and secretory proteins that are difficult to express in conventional systems. Such proteins include vaccine antigens, monoclonal antibodies, and a variety of therapeutic proteins for the treatment and prevention of human and animal disease.

Total Funding Amount:

$8.09M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Ithaca, New York, United States

Founded Date:

2004-01-01

Contact Email:

info(AT)tetragenetics.com

Founders:

Bill Gordon

Number of Employees:

11-50

Last Funding Date:

2020-09-29

IPO Status:

Private

Industries:

© 2025 bioDAO.ai